Why the study?
Does aprotinin increase safety risks, such as renal events, compared to tranexamic acid in patients having heart surgery?
Does aprotinin increase safety risks, such as renal events, compared to tranexamic acid in patients having heart surgery?
This review discusses recent literature questioning the safety of aprotinin, specifically regarding increased renal events compared to tranexamic acid, in patients undergoing heart surgery.
Concerns over renal events with aprotinin versus tranexamic acid in cardiac surgery warrant caution; leaves open need for randomized confirmation.
Recent articles published in peer review journals have questioned the safety of using aprotinin in patients having heart surgery. Also, evidence has been published to suggest an increase in renal events in patients given aprotinin when compared to those where tranexamic acid was used. The present review will focus principally on the first of these articles in relation to previously published data and experience.
No takes yet. Share an insight, caveat, or question.
Royston et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: